NO970631L - Fremgangsmåter for behandling av sepsis eller betennelsessykdommer med oxypurin-nukleosider - Google Patents

Fremgangsmåter for behandling av sepsis eller betennelsessykdommer med oxypurin-nukleosider

Info

Publication number
NO970631L
NO970631L NO970631A NO970631A NO970631L NO 970631 L NO970631 L NO 970631L NO 970631 A NO970631 A NO 970631A NO 970631 A NO970631 A NO 970631A NO 970631 L NO970631 L NO 970631L
Authority
NO
Norway
Prior art keywords
methods
inflammatory diseases
oxypurine nucleosides
treating sepsis
treating
Prior art date
Application number
NO970631A
Other languages
English (en)
Norwegian (no)
Other versions
NO970631D0 (no
Inventor
Reid W Von Borstel
Michael K Bamat
Bradley M Hiltbrand
James C Butler
Shyam Shirali
Original Assignee
Pro Neuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc
Publication of NO970631D0 publication Critical patent/NO970631D0/no
Publication of NO970631L publication Critical patent/NO970631L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO970631A 1994-08-12 1997-02-11 Fremgangsmåter for behandling av sepsis eller betennelsessykdommer med oxypurin-nukleosider NO970631L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28921494A 1994-08-12 1994-08-12
PCT/US1995/010078 WO1996004923A1 (en) 1994-08-12 1995-08-08 Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides

Publications (2)

Publication Number Publication Date
NO970631D0 NO970631D0 (no) 1997-02-11
NO970631L true NO970631L (no) 1997-04-11

Family

ID=23110539

Family Applications (3)

Application Number Title Priority Date Filing Date
NO970631A NO970631L (no) 1994-08-12 1997-02-11 Fremgangsmåter for behandling av sepsis eller betennelsessykdommer med oxypurin-nukleosider
NO20016068A NO317199B1 (no) 1994-08-12 2001-12-12 Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat for redusering av inflammasjon i et dyr
NO20041007A NO20041007L (no) 1994-08-12 2004-03-10 Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20016068A NO317199B1 (no) 1994-08-12 2001-12-12 Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat for redusering av inflammasjon i et dyr
NO20041007A NO20041007L (no) 1994-08-12 2004-03-10 Anvendelse av oksypurin-nukleosider for fremstilling av et farmasoytisk preparat

Country Status (12)

Country Link
US (1) US20040235782A1 (de)
EP (2) EP1157698A3 (de)
JP (2) JPH10507441A (de)
KR (1) KR100290129B1 (de)
AU (1) AU712835B2 (de)
CA (1) CA2197205A1 (de)
FI (1) FI970588A7 (de)
IL (1) IL114887A0 (de)
NO (3) NO970631L (de)
RU (1) RU2203669C2 (de)
WO (1) WO1996004923A1 (de)
ZA (1) ZA956679B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
DE60144277D1 (de) * 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
WO2004029055A1 (en) 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
US6997018B2 (en) 2003-06-02 2006-02-14 Ferro Corporation Method of micro and nano texturing glass
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
CA2695950C (en) 2007-08-16 2016-06-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions containing nucleosides and manganese and their uses
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP2012524126A (ja) 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー 固形腫瘍の治療方法
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
CA2797716C (en) * 2010-04-29 2018-09-11 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
EP3083630B1 (de) 2013-12-20 2019-08-21 Gilead Calistoga LLC Prozessverfahren für phosphatidylinositol-3-kinase-hemmer
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EP4280876A1 (de) * 2020-08-24 2023-11-29 Adama Makhteshim Ltd. Pestizidverbindungen und zusammensetzungen, verfahren zur verwendung und verfahren zur herstellung davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529205A (en) * 1983-10-20 1985-07-16 Bowker Dennis E Winery game board
CA2444071C (en) * 1991-02-08 2008-10-07 Wellstat Therapeutics Corporation Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
US5320846A (en) * 1991-04-17 1994-06-14 New England Deaconess Hospital Corp. Method and composition for testing patients with metabolic depleting diseases

Also Published As

Publication number Publication date
NO20016068D0 (no) 2001-12-12
NO20016068L (no) 1997-04-11
NO20041007L (no) 2004-03-10
EP1157698A3 (de) 2002-05-02
FI970588A0 (fi) 1997-02-12
FI970588L (fi) 1997-04-11
ZA956679B (en) 1997-02-10
NO970631D0 (no) 1997-02-11
WO1996004923A1 (en) 1996-02-22
KR970704457A (ko) 1997-09-06
CA2197205A1 (en) 1996-02-22
AU3278495A (en) 1996-03-07
FI970588A7 (fi) 1997-04-11
US20040235782A1 (en) 2004-11-25
JPH10507441A (ja) 1998-07-21
RU2203669C2 (ru) 2003-05-10
AU712835B2 (en) 1999-11-18
JP2009221221A (ja) 2009-10-01
EP0771204A4 (de) 1999-10-20
EP1157698A2 (de) 2001-11-28
IL114887A0 (en) 1995-12-08
KR100290129B1 (ko) 2001-05-15
EP0771204A1 (de) 1997-05-07
NO317199B1 (no) 2004-09-13

Similar Documents

Publication Publication Date Title
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
EP0313305A3 (de) Chelatbildner enthaltende Lichtschutzmittel
TR199800825T2 (xx) Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri.
LV12209A (lv) Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori
TR199801168T2 (xx) �nterleukin-1 beta d�n��t�r�c� enzim inhibit�rleri.
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
EA200100623A1 (ru) Кетолидные антибиотики
NO20006323D0 (no) Glykopeptidderivater og farmasöytiske sammensetninger som inneholder disse
BR9303993A (pt) Composto, processo para preparar o mesmo e composição farmacêutica
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
EP0620251A3 (de) Mischbare Polyolefin-Mischungen.
AR005999A1 (es) Nuevos derivados de eritromicina, su procedimiento de preparacion, composiciones farmaceuticas y medicamentos
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
FI970588A7 (fi) Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä
EA200400701A1 (ru) 13-членные азалиды и их применение в качестве антибиотических агентов
PE20001297A1 (es) Antibioticos cetolidos carbamato y carbazato
DE69126460D1 (de) Benzisothiazolinon-1-dioxyde als Elastase-Inhibitoren
ATE179615T1 (de) Oxypurin-nukleoside und seine artverwandten, und acylderivate davon, zur verbesserung der hämatopoese
DK0888323T3 (da) Dihydrobenzofuran og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
DK164191C (da) Fungicid og fremgangsmaader til dets fremstilling og til dets anvendelse til bekaempelse af svampe
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
EA199800534A1 (ru) ПРИМЕНЕНИЕ 2-ЭТИЛГЕКСИЛ-α-ЦИАНО-β, β-ДИФЕНИЛАКРИАТА ДЛЯ УЛУЧШЕНИЯ СТАБИЛЬНОСТИ КОСМЕТИЧЕСКИХ КОМПОЗИЦИЙ, СОДЕРЖАЩИХ П-МЕТИЛБЕНЗИЛИДЕНКАМФОРУВ СОЧЕТАНИИ С ДИБЕНЗОИЛМЕТАНОВЫМ ПРОИЗВОДНЫМ
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application